CliffBio
biologic

TNKase

tenecteplase

Loss of exclusivityJune 2012projected — 12-year biologic exclusivity estimate
CompanyGenentech →See this company's full patent-cliff portfolio

Drug detail

Brand nameTNKase
Active ingredienttenecteplase
Strength50MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalJune 2000
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

TNKase patent cliff — loss of exclusivity June 2012 | CliffBio